Health & bio
Otarmeni Receives Accelerated Approval for Hereditary Hearing Loss on April 23
FDA expedited lunsotogene parvec-cwha approval, broadening the gene-therapy footprint in rare diseases.
Primary sources · 1
FDA expedited lunsotogene parvec-cwha approval, broadening the gene-therapy footprint in rare diseases.
7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.